医疗保健特许权投资公司向ADC Therapeutics SA授予了约980万股普通股的认购权证。根据协议条款,每份权证的行权价格确定为每股3.81美元。此次权证授予将为ADC Therapeutics SA带来潜在的资本注入,同时为投资者提供了未来以固定价格购入该公司普通股的权利。
医疗保健特许权投资公司向ADC Therapeutics SA授予了约980万股普通股的认购权证。根据协议条款,每份权证的行权价格确定为每股3.81美元。此次权证授予将为ADC Therapeutics SA带来潜在的资本注入,同时为投资者提供了未来以固定价格购入该公司普通股的权利。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.